8-K: Kaya Holdings Opens Psilocybin Treatment Center, CEO to Undergo First Treatment

Kaya Holdings, Inc. has announced the grand opening of its psilocybin treatment center, The Sacred Mushroom, in Portland, Oregon, with the CEO being the first to receive treatment.

Summary

• Kaya Holdings, Inc. (KAYS) has announced the opening of its psilocybin treatment center, The Sacred Mushroom (TSM), in Portland, Oregon, on July 5, 2024.
• The center will offer psilocybin treatments to eligible guests seeking to explore the potential benefits of psilocybin for mental health and well-being.
• KAYS CEO Craig Frank will be the first guest to receive a psilocybin treatment at TSM to experience the setting and ensure it meets the highest standards.
• The company has spent eighteen months preparing for the opening of The Sacred Mushroom.
• KAYS is among a limited number of companies legally licensed to offer psilocybin treatments.
• TSM aims to provide a gateway for individuals seeking fulfillment, inspiration, and inner peace, as well as offer alternative treatments for mental health disorders.
• The center is now scheduling psilocybin treatment sessions for qualified guests, with a fully functioning website expected within the week.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook with the opening of the psilocybin treatment center and the CEO's personal involvement. However, there are risks associated with the business, including the need for final financing and regulatory uncertainties.

Positives

• Kaya Holdings is expanding into the emerging psilocybin sector with the opening of The Sacred Mushroom.
• The company is among the first to legally offer psilocybin treatments.
• The center aims to address a range of mental health issues, offering an alternative treatment pathway.
• The CEO's personal involvement in the first treatment demonstrates commitment to the center's quality and experience.
• The company has a history of being a first mover in the cannabis industry, and is now doing the same in the psilocybin sector.

Negatives

• The launch of The Sacred Mushroom is dependent on receiving final financing from investors.
• The company acknowledges that changes in federal, state, or local laws could adversely affect business operations and stockholder value.
• The company is still in the early stages of developing its psilocybin business.

Risks

• The success of The Sacred Mushroom is dependent on securing final financing.
• Changes in laws and regulations regarding psychedelics could negatively impact the business.
• The company faces competition in the emerging psilocybin market.
• The acceptance of psilocybin treatments by the public and the medical community is not guaranteed.
• The company's business plan is subject to legal advice and may be altered based on that advice.

Future Outlook

The company plans to execute its business objectives in accordance with current understanding of state and local laws and federal enforcement policies. The company will obtain advice of counsel prior to actualizing any portion of their business plan. The company is working to make the TSM facility a success and create stockholder value.

Management Comments

• KAYS CEO Craig Frank stated he is going to experience psilocybin for the first time as the initial guest of The Sacred Mushroom.
• Craig Frank stated his primary goal is to experience TSM as any guest would.
• Craig Frank stated he wants to be certain that the company has created the setting and has all the activities and amenities necessary to deliver the highest standard of legal psilocybin experience available anywhere in the world.
• W. David Jones, KAYS Senior Advisor, thanked Craig Frank for his hands-on leadership.

Industry Context

This announcement positions Kaya Holdings as a player in the emerging psilocybin treatment sector, which is gaining traction as an alternative approach to mental health care. The company is leveraging its experience in the cannabis industry to enter this new market.

Comparison to Industry Standards

• While specific financial benchmarks for psilocybin treatment centers are still developing, Kaya Holdings is positioning itself as a first mover in this space, similar to its early entry into the cannabis market.
• The company's focus on providing a high-quality experience, as evidenced by the CEO's personal involvement, aligns with the emerging standards for psilocybin treatment centers.
• Comparible companies include those in the early stages of the psilocybin sector such as MindMed, Compass Pathways, and Atai Life Sciences, however, these companies are focused on drug development and clinical trials, rather than treatment centers.

Stakeholder Impact

• Shareholders may see potential growth in the company's value with the expansion into the psilocybin sector.
• Employees will be involved in the operation of the new treatment center.
• Customers will have access to psilocybin treatments for mental health and well-being.
• The company's suppliers will benefit from the increased demand for goods and services.
• Creditors may see increased confidence in the company's ability to repay debts.

Next Steps

• The Sacred Mushroom will begin scheduling psilocybin treatment sessions for qualified guests.
• The company will launch a fully functioning website for The Sacred Mushroom within the week.
• The company will continue to seek final financing for the launch of The Sacred Mushroom.

Key Dates

Keywords

psilocybin, treatment center, mental health, psychedelics, Kaya Holdings, The Sacred Mushroom, Craig Frank, OTCQB:KAYS, Fifth Dimension Therapeutics, cannabis